Neuphoria Therapeutics (NEUP) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Quantum Biopharma (QNTM) has outperformed Neuphoria Therapeutics (NEUP) over the past year, losing 80.3% versus a loss of 81.8%. Quantum Biopharma is the larger company by market cap ($18.9 million vs $18.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEUP | QNTM |
|---|---|---|
| Share price | $3.36 | $2.94 |
| Market cap | $18.18M | $18.90M |
| 1-day change | +0.30% | -5.47% |
| YTD return | -13.66% | -57.40% |
| 1-year return | -81.76% | -80.28% |
| 5-year return | — | -96.65% |
| EPS (TTM) | $-3.06 | $-4.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.21 | $16.36 |
| 52-week low | $3.19 | $2.07 |
| Distance from 52-week high | -82.51% | -82.03% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +317.35% |
| Average volume | 161.66K | 205.30K |
| Shares outstanding | 5.41M | 6.43M |
| Employees | 1 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Health Care · Biotechnology: Pharmaceutical Preparations
NEUP vs QNTM FAQ
Which is bigger, Neuphoria Therapeutics or Quantum Biopharma?
Quantum Biopharma (QNTM) is larger, with a market capitalization of $18.90M compared with $18.18M for Neuphoria Therapeutics (NEUP).
Which stock has performed better over the past year, NEUP or QNTM?
QNTM returned -80.28% over the past 12 months, compared with -81.76% for NEUP (price return, excluding dividends). Past performance does not predict future results.
Are Neuphoria Therapeutics and Quantum Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.